Welcome to CoRegen, Inc: A Leader in Novel Cancer Treatments
CoRegen, Inc, a biopharmaceutical company based in Houston, TX, recently secured over $93M in funding to further develop groundbreaking treatments for aggressive forms of cancer. The company plans to use this investment to advance its chemistry, manufacturing, and controls (CMC) development, as well as launch a Phase 1/2 clinical trial for its SRC3-KO program targeting solid-tumor types.
One of CoRegen’s key innovations is its approach to cancer treatment, which involves targeting the SRC-3 gene in Regulatory T (Treg) cells. By genetically modifying Tregs, the immune system can better recognize and eliminate solid tumors. This approach has shown promising results in preclinical models, with Tregs being able to penetrate tumors, release cytokines, and recruit immune cells to eradicate cancer.
This latest funding round follows a previous $28M raise in early 2024, which allowed CoRegen to acquire an exclusive license from Baylor College of Medicine for its gene regulatory platform. With a focus on innovation and growth, CoRegen continues to make strides in the field of cancer treatment and looks to expand its leadership team to support future success.
